Who is sponsoring NCT03112655?

NCT03112655 is sponsored by Institut de Recherche pour le Developpement.

What drugs are being tested in NCT03112655?

Interventions in NCT03112655: RNA and neopterin detection.

What condition does NCT03112655 study?

NCT03112655 studies African Trypanosomiasis, African; Trypanosomiasis, West, Sleeping Sickness; West African, Trypanosoma Brucei Gambiense; Infection.

Is NCT03112655 still recruiting?

NCT03112655 is currently completed. Last updated 21 February 2021.

Last reviewed 2021-02-21 · How we verify

NCT03112655: DiTECT-WP4

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: Early Test-of-cure

Completed NA Last updated 21 February 2021

What this trial tests

NA trial testing RNA and neopterin detection in African Trypanosomiasis in 88 participants. Completed in 31 January 2021.

Timeline

24 February 2017

Primary endpoint
31 January 2021

31 January 2021

Quick facts

Lead sponsor	Institut de Recherche pour le Developpement
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	diagnostic
Enrollment	88
Start date	24 February 2017
Primary completion	31 January 2021
Estimated completion	31 January 2021
Sites	1 location across Democratic Republic of the Congo

Drugs / interventions tested

RNA and neopterin detection

Conditions studied

African Trypanosomiasis — all drugs for African Trypanosomiasis →
African; Trypanosomiasis, West — all drugs for African; Trypanosomiasis, West →
Sleeping Sickness; West African — all drugs for Sleeping Sickness; West African →
Trypanosoma Brucei Gambiense; Infection — all drugs for Trypanosoma Brucei Gambiense; Infection →

Sponsor

Institut de Recherche pour le Developpement — full company profile →

Who can join

15 and older, any sex, with African Trypanosomiasis or African; Trypanosomiasis, West. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study validates the diagnostic performance of cerebrospinal fluid neopterin quantification and of blood and cerebrospinal fluid trypanosomal spliced leader RNA detection for assessing outcome after treatment of human African trypanosomiasis.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Trypanosome SL-RNA detection in blood and cerebrospinal fluid to demonstrate active gambiense human African trypanosomiasis infection.
Ngay Lukusa I, Van Reet N, Mumba Ngoyi D, Miaka EM, et al · · 2021 · cited 9× · PMID 34534223 · DOI 10.1371/journal.pntd.0009739
Trypanosome spliced leader RNA for diagnosis of acoziborole treatment outcome in gambiense human African trypanosomiasis: A longitudinal follow-up study.
Ngay Lukusa I, Van Reet N, Mumba Ngoyi D, Mwamba Miaka E, et al · · 2022 · cited 4× · PMID 36436279 · DOI 10.1016/j.ebiom.2022.104376

Verify or expand the search:

Other Institut de Recherche pour le Developpement trials

Trials by the same sponsor.

NCT07181278 — Optimization of Cervical Cancer Screening Strategies Among Women Living With HIV: Effectiveness and Implementation of De · NA · recruiting
NCT05581212 — TB Case-Finding, Treatment and Prevention Intervention in Thailand · NA · not yet recruiting
NCT06503393 — SENOVIE France - Therapeutic Mobility and Breast Cancer · completed
NCT05466630 — Prospective Evaluation of the Specificity of Serological Tests for Human African Trypanosomiasis · NA · completed
NCT05091489 — ANRS 12415 - Quali PrEP Cambodia · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03112655 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut de Recherche pour le Developpement
Last refreshed: 21 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03112655.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing